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Abstract Parkinson’s disease (PD) is a complex pro-
gressive movement disorder leading to motor and non-
motor symptoms that become increasingly debilitating as
the disease advances, considerably reducing quality of life.
Advanced treatment options include deep brain stimulation
(DBS). While clinical effectiveness of DBS has been
demonstrated in a number of randomised controlled trials
(RCT), evidence on cost-effectiveness is limited. The cost-
effectiveness of DBS combined with BMT, versus BMT
alone, was evaluated from a UK payer perspective. Indi-
vidual patient-level data on the effect of DBS on PD
symptom progression from a large 6-month RCT were used
to develop a Markov model representing clinical progres-
sion and capture treatment effect and costs. A 5-year time
horizon was used, and an incremental cost-effectiveness
ratio (ICER) was calculated in terms of cost per quality-
adjusted life-years (QALY) and uncertainty assessed in
deterministic sensitivity analyses. Total discounted costs in
the DBS and BMT groups over 5 years were £68,970 and
£48,243, respectively, with QALYs of 2.21 and 1.21, giv-
ing an incremental cost-effectiveness ratio of £20,678 per
QALY gained. Utility weights in each health state and
costs of on-going medication appear to be the key drivers
of uncertainty in the model. The results suggest that DBS is
a cost-effective intervention in patients with advanced PD
who are eligible for surgery, providing good value for
money to health care payers.
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Introduction
Parkinson’s disease (PD) is a progressive degenerative
brain disorder of adult onset (average age 59 years [1]) that
is estimated to affect between 0.129 and 0.151 % of the
general population in Europe [2–5]. The disease is char-
acterised by motor and non-motor symptoms; as PD
advances into the complicated and late stages, motor
symptoms increase in severity and frequency, freezing of
gait can occur and medication-induced motor complica-
tions such as unpredictable fluctuations in symptoms and
dyskinesias emerge. It is estimated that 40 % of patients
experience these complications after the first 5 years from
PD diagnosis, despite best medical therapy (BMT) [6].
Parkinson’s disease of all severities can have a signifi-
cant impact upon patients’ quality of life (QoL) [7–12],
mainly due to increased disability, pain, motor complica-
tions and falls [13–25]. As the disease progresses, the
mental, physical, social and emotional domains of patients’
QoL decrease significantly [26]. High costs are incurred
during the course of PD in terms of drug therapy,
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hospitalisations and fall-related injuries; European studies
have estimated that the total cost per PD patient is
€10,000–14,000 per year, of which approximately €6,000
is due to lost productivity [27, 28]. Costs increase signifi-
cantly with disease progression [27, 29].
The management of patients with PD varies according
to disease stage and consists mainly of drug therapy. For
advanced disease, the European Federation of Neurologi-
cal Societies (EFNS) recommends various oral drug
therapies as monotherapy or combination therapy [30]. As
patients become refractory to oral drugs despite BMT,
deep brain stimulation (DBS) has been shown to be an
effective therapy in combination with BMT, versus BMT
alone [31–36]. In the UK, current guidance from the
National Institute for Health and Clinical Excellence
(NICE) recommends the use of DBS for patients who
have motor complications and who are refractory to
medical treatment [37, 38].
The majority of existing cost-effectiveness analyses
[39–42] have limitations as they report short-term results
only [39], represent health states using non-standard mea-
sures such as nursing home status as opposed to formal
disease modelling [40], or have not carried out a formal
cost-effectiveness analysis [41]; no analysis has been based
on patient-level randomised controlled trial (RCT) data or
has used the UK NHS perspective. Our study objective was
to develop a new cost-effectiveness model to compare
interventions in advanced PD, based on patient-level RCT
data using longer-term costs and disease outcomes. Spe-
cifically, our analysis sought to estimate the cost-utility of
DBS in combination with BMT, compared with BMT




We developed a Markov model using patient-level data
from the 6-month RCT by Deuschl et al. [31], which
compared DBS plus BMT vs. BMT alone in 156 patients
with advanced PD. The study evaluated changes in quality
of life via the Parkinson’s disease questionnaire (PDQ-39),
and changes in symptom severity using Part III of the
UPDRS. The study also recorded H&Y stage at each visit
(ranging from 0 to 5, 0 representing a patient free of PD
symptoms and stage 5 representing a wheelchair-bound
patient requiring constant nursing care) [43], level of ‘OFF’
time (proportion of the waking day in which the patient’s
medication is not providing adequate symptom control)
and a series of demographic parameters.
The model defines health states according to the H&Y
stages (1–5), with each state split into four sub-states to
represent the level of ‘OFF’ time (see Fig. 1). In addition,
death was included as an absorbing state. A Markov
approach was deemed suitable given the logical separation
of patients into these various disease stages. A 6-month
cycle length was used, given that the available trial data
consisted of a baseline and 6-month visit, together with a
5-year time horizon to reflect the uncertainty in long-term
outcomes while also capturing the costs associated with
device replacement. A UK NHS perspective on costs was
adopted, with both costs and quality-adjusted life-years
(QALYs) discounted at 3.5 % per annum, in line with
recommendations from NICE [44].
In each cycle, patients could worsen by one H&Y stage,
progress by one level of ‘OFF’ time, or both. If none of
these events occurred, the patient remained in the same
health state in the next model cycle. The model assumed
that, after the first 6 months of treatment, patients’ H&Y
stage or ‘OFF’ time cannot be improved further. Any
patient withdrawing from treatment in the DBS arm was
assumed to immediately progress to the next worst ‘OFF’
time state, to reflect the expected reduction in symptom
control when the device is switched off or explanted.
Table 1 summarises the key model input parameters.
Fig. 1 Model health states (H&Y and ‘OFF’ time). The H&Y scale
focuses on motor symptoms and classifies patients into one of six
categories (ranging from 0 to 5) according to disease severity, with 0
representing a patient free of PD symptoms and stage 5 representing a
wheelchair-bound patient requiring constant nursing care. The
amount of time a patient spends in the ‘OFF’ state per day is an
aspect of the UPDRS, which assesses various aspects of the disease,
including mental status, motor function and complications of therapy,
and assigns a total score to each patient reflecting an overall estimate
of the degree of disability
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Table 1 Model input parameters and values
Parameters Value Source/comment
6-month probability of progression
H&Y 1 to 2 0.188 Zhao et al. [45]
H&Y 2 to 3 0.04 Zhao et al. [45]
H&Y 3 to 4 0.159 Zhao et al. [45]
H&Y 4 to 5 0.148 Zhao et al. [45]
6-month probability of progression
0–25 to 26–50 % ‘OFF’
time
0.127 Palmer et al. [46, 47]
26–50 to 51–75 % ‘OFF’
time
0.074 Palmer et al. [46, 47]
51–75 to 76–100 % ‘OFF’
time
0.043 Palmer et al. [46, 47]
Utilities in H&Y 1
0–25 % OFF time 0.74 Palmer et al. [46]
26–50 % OFF time 0.68 Palmer et al. [46]
51–75 % OFF time 0.64 Palmer et al. [46]
76–100 % OFF time 0.52 Palmer et al. [46]
Utilities in H&Y 2
0–25 % OFF time 0.72 Palmer et al. [46]
26–50 % OFF time 0.72 Palmer et al. [46]
51–75 % OFF time 0.66 Palmer et al. [46]
76–100 % OFF time 0.49 Palmer et al. [46]
Utilities in H&Y 3
0–25 % OFF time 0.643 Lowin et al. [48]
26–50 % OFF time 0.555 Lowin et al. [48]
51–75 % OFF time 0.467 Lowin et al. [48]
76–100 % OFF time 0.379 Lowin et al. [48]
Utilities in H&Y 4
0–25 % OFF time 0.387 Lowin et al. [48]
26–50 % OFF time 0.299 Lowin et al. [48]
51–75 % OFF time 0.211 Lowin et al. [48]
76–100 % OFF time 0.123 Lowin et al. [48]
Utilities in H&Y 5
0–25 % OFF time 0.131 Lowin et al. [48]
26–50 % OFF time 0.043 Lowin et al. [48]
51–75 % OFF time -0.045 Lowin et al. [48]
76–100 % OFF time -0.133 Lowin et al. [48]
Relative risks of mortality
H&Y 2 (vs. H&Y 1) 2.03 Liou et al. [49]
H&Y 3 (vs. H&Y 1) 2.16 Liou et al. [49]
H&Y 4 (vs. H&Y 1) 4.99 Liou et al. [49]
H&Y 5 (vs. H&Y 1) 4.99 Liou et al. [49]
Drug dosing
Daily levodopa dose (mg)
in BMT arm (first cycle)
220 Deuschl et al. [31]
Daily levodopa dose (mg)
in BMT arm (subsequent
cycles)
205 Deuschl et al. [31]
Daily levodopa dose (mg)
in DBS arm (first cycle)
213 Deuschl et al. [31]
Table 1 continued
Parameters Value Source/comment
Daily levodopa dose (mg)
in DBS arm (subsequent
cycles)
188 Deuschl et al. [31]
Adverse events—DBS (per cycle)
System infections per
patient during first cycle
(12 out of 121 patients
had a total of 16
infections)




0.026 Deuschl et al. [31]
Probability per cycle of
lead dislodgement
0.066 Weaver et al. [32]
Probability of withdrawal
from DBS during first
cycle
0.1 Deuschl et al. [31]
Probability of withdrawal
from DBS during each
subsequent cycle
0.02 Assumption
Adverse events—both treatment arms
Number of falls per
cycle for patients
with H&Y 3
3.15 Pickering et al. [50]
Relative risk of fall for
patient with H&Y 4 or 5
(vs. H&Y 3)
1.72 Pickering et al. [50]
Probability of
hospitalisation per fall
0.62 Bloem et al. [51]
Treatment withdrawal rates
Probability of withdrawal
from DBS during first
cycle
0.1 Deuschl et al. [31]
Probability of withdrawal




Cost per cycle of drugs in
BMT arm (excluding
levodopa) or for DBS
patients who’ve
withdrawn
£3,725 McIntosh et al. [52]
Cost per cycle of drugs in
DBS arm (excluding
levodopa)





£0.07 British National Formulary
No. 62 (2011) [53]
Cost parameters—treatment initiation, materials and implantation
Pre-operative assessment/
work-up
£641 Payment by results tariffs
(2011–2012) code:
AA25Z [54]
DBS device £8,326 Medtronic UK price list.
Activa IPG, model
number 37,601 [55]
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Patient-level efficacy data
The trial data comprised baseline and 6-month data on
H&Y stage and level of ‘OFF’ time for each patient,
enabling us to estimate the state populations at these two
time points. Figure 2 shows the split of patients between
the H&Y stages in each arm at baseline and 6 months.
Since our model also addresses the amount of ‘OFF’ time
per patient, we also compared the two arms on this out-
come at baseline and 6 months (Fig. 3).
We used the data from Figs. 2 and 3 to represent the
changes in patients’ H&Y stage and level of ‘OFF’ time
between baseline and 6 months, and subsequently mod-
elled long-term progression of PD in two ways. Although
long-term studies of DBS in PD patients do exist, the data
available from these studies was not sufficiently detailed to
allow disease progression probabilities to be estimated
between the health states in the model. We therefore
modelled progression of patients’ underlying disease stage
using data reported between the various H&Y stages [45].
Using the time-to-event curves reported for each progres-
sion event (e.g. H&Y 1–H&Y 2, H&Y 2–H&Y 3), we
calculated 6-month probabilities of progression between
each successive H&Y stage and applied these to both arms
of the model from 6 months onwards. We also modelled
worsening of ‘OFF’ time using data from previous eco-
nomic evaluations [46, 47], again applying these proba-
bilities equally to both treatment arms.
Mortality
The trial data reported that a total of four patients died
during the 6-month follow-up period (three in the DBS
group, and one in the BMT group) [31]. Of the deaths in
the DBS group, one was due to a cerebral haematoma, one
patient committed suicide, and one died of pneumonia; in
the BMT group, the single death was due to a car accident.
With the exception of the cerebral haematoma, none of
these deaths were considered to be related to the inter-
ventions received (recent evidence has shown no associa-
tion between DBS and an increased risk of suicide [57])
and so the remaining three deaths were excluded from the
mortality calculations in the model.
In order to capture the effect of increased mortality risk
for individuals with PD and the relationship between dis-
ease status and mortality, we used age-specific all-cause
general population mortality rates from the UK [58], to
which we applied relative risks within each H&Y stage to
reflect increasing mortality risk with disease progression,
using data from a community-based study [49].
Quality of life
To capture the effects of PD progression upon patients’
QoL, we applied utility weights to each of the health states
in the model. Although PDQ-39 data were collected at both
visits within the key clinical study [31], there is currently
no adequate tool for mapping these data to a generic
Table 1 continued
Parameters Value Source/comment
DBS extensions (cost of 2
extensions)




DBS leads (cost of 2
leads)
£1,786 Medtronic UK price list.
Lead kit, model numbers
338,728, 338,740 [55]






£7,131 Payment by results tariffs
(2011–2012) Code:
AA072Z [54]
Cost parameters—adverse event management
Infection (DBS) £10,690 Payment by results tariffs
(2011–2012) codes:
AA04Z and PA18B [54].
Plus costs of new device,
leads and extensions for
serious infections.
Lead dislodgement (DBS) £8,789 Repeat implantation














£217 Payment by results tariffs
(2011–2012) code: 400
(non-mandatory) [54]
Hospitalisation due to fall
(all arms)





follow-up visit (1 visit in
first cycle post-
implantation of DBS)





(3 visits per 6 months
assumed in all arms)
£217 Payment by results tariffs
(2011–2012) code: 400
(non-mandatory) [54]
Cost per PD nurse visit (3
home visits assumed per
6 months in all arms)
£114 Curtis [56]
DBS deep brain stimulation, H&Y Hoehn and Yahr, PD Parkinson’s
disease
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measure of QoL suitable for use in decision-analytic
modelling e.g., EQ-5D. For this reason, we used utility data
from two previous economic evaluations [46, 48], which
provided utility estimates covering all of the health states
included in our model (i.e., for each combination of H&Y
and ‘OFF’ time). The modelled benefit of DBS was
therefore based on the distribution of patients between
health states with different utilities, rather than through
separate modelling of treatment-specific utilities.
Resource use and costs
The model included the relevant costs relating to each treat-
ment arm: device acquisition and implantation; adverse event
management (infection, lead dislodgement, battery exhaus-
tion, hospitalisation for falls); PD nurse home visits (three per
cycle); drug therapy (levodopa and other anti-Parkinson
medication); routine follow-up (three neurology outpatient
visits per cycle). The DBS arm was associated with the up-
front costs of the device and its implantation, including a pre-
operative assessment, to which were added the costs of
device-related complications (infections and lead displace-
ments). The majority of infections occur at the site of the pulse
generator soon after implantation (12 patients out of 121 had a
total of 16 infections over 6 months, thus a rate of 0.132 per
patient was assumed) [32] and are relatively more easily
managed, while in other cases the infection spreads to the
leads situated in the brain, requiring a full explantation of the
system. Our analysis conservatively assumed that half of
infections are of the severe type requiring system explanta-
tion, with the cost applied according to this weighting. The
baseline rate of falls was assumed to be 3.15 per cycle for
patients in H&Y 3 [50]; no falls were assumed in H&Y 1 or 2,
and relative risks were applied to the baseline rate to reflect
higher fall rates in H&Y 4; 5.60 % of falls were assumed to
result in hospitalisation [51].
Drug costs were estimated via levodopa use data from the
key clinical study [31], together with data reported on drug
Fig. 2 Hoehn and Yahr stage at
baseline and 6 months [31]
Fig. 3 ‘OFF’ time at baseline
and 6 months [31]
110 J Neurol (2014) 261:106–116
123
therapy costs from a separate DBS study [52]. For device
replacement, which is assumed to occur at 4 years (based on
the Medtronic ActivaPC DBS device), we applied the cost of
a new device plus the procedure cost for making the
replacement. In addition, the costs associated with any new
infections arising from these replacements were included.
Follow-up costs in both arms were based on the assumption of
three neurology outpatient appointments and three PD nurse
visits per cycle, which would cover general follow-up,
including adjustment of the DBS stimulation parameters.
These assumptions were validated with clinical experts and
were applied equally to both arms of the model. A per-cycle
probability of withdrawal from DBS was applied, after which
on-going management costs for these patients were assumed
to be equivalent to patients in the BMT arm. The cost of
management of cerebral haematoma in the DBS group was
excluded from the cost analysis, since the death observed in
the clinical study occurred during the procedure and would
therefore be covered by the tariff paid to the hospital for the
DBS implantation procedure.
The cost year used was 2011. Price uplifts were used
where necessary to inflate costs to current values.
Cost-utility analysis
The primary outcome of interest from cost-effectiveness
analyses and from this model is the incremental cost-
effectiveness ratio (ICER), which describes the additional
cost per health unit gained. In this model, we calculated the
cost-utility in terms of the cost per QALY gained. The
ICER is calculated as follows for the treatment comparison
being made in this study:
ICER ¼ CDBS  CBMT
QDBS  QBMT
where CDBS and CBMT represent the total costs associated
with the DBS and BMT groups, respectively, and QDBS and
QBMT represent the total QALYs for each intervention.
Sensitivity analysis
In order to explore the impact of parameter uncertainty upon
the cost-effectiveness results, a series of one-way sensitivity
analyses was undertaken to identify key parameters in the
model. The results can then be presented in the form of a
tornado diagram, which shows the relative importance of
each input parameter in terms of the effect upon the ICER of
using smaller and large values of each input. The range
chosen for each input value was based either on the published
confidence interval or upon plausible alternative values from
the literature. For example, two different scenarios for the
utility weight parameters were explored, using utilities
reported from two alternative quality of life studies [59, 60].
Results
Base-case analysis
Table 2 shows the discounted results of the base-case cost-
effectiveness analysis over a 5-year time horizon. These
results give an incremental cost-effectiveness ratio (ICER)
of £20,678 per QALY gained. The incremental costs in the
DBS arm were largely made up of the costs of the device
and its implantation, although some of these costs were
offset by reduced drug use (both levodopa and other anti-
Parkinson medication) and fewer falls. The initial clinical
benefit observed in the DBS arm of the key clinical study
[31] (in terms of improved H&Y stage and reduced ‘OFF’
time) was projected to translate into a substantial QALY
gain for these patients over the 5-year period. The model
predicted a modest survival gain for patients in the DBS
arm (approximately 1 month on average over the model
horizon), which was observed due to the increasing risk of
death applied for patients in H&Y 4 and 5 (the 5-year
mortality rates predicted by the model were 13.7 and
17.2 % for the DBS and BMT arms, respectively).
Sensitivity analysis
Figure 4 shows the results of the one-way sensitivity ana-
lysis in the form of a tornado diagram. The most influential
parameters, in terms of their effect upon the ICER, appear
at the top of the chart (those with the widest bars).
There was minimal effect upon the ICER for many of
the model parameters. The key inputs were the utility
weights applied to each health state. When QoL was con-
sidered to vary by H&Y stage only (i.e., the effect of ‘OFF’
time on QoL is ignored) and utility data from a different
economic evaluation used [59], the ICER increased to
£64,170 (the extreme right of the top bar in the chart)—this
result differed greatly from the base-case result because of
the greater similarity of utility weights in each H&Y stage
from that study. A separate study reported a wider spread
of utility weights across the H&Y stages [60], resulting in
an ICER more consistent with the base-case result (£18,650
per QALY gained—see the extreme left of the top bar in
the chart). A further sensitivity analysis on the QoL data
Table 2 Base-case cost-effectiveness results
Treatment Costs QALYs
BMT £48,243 1.21
DBS ? BMT £68,970 2.21
Incremental £20,727 1.002
BMT best medical treatment, DBS deep brain stimulation, QALY
quality adjusted life year
J Neurol (2014) 261:106–116 111
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applied utility weights from a different study to the four
levels of ‘OFF’ time (thus ignoring any differences in QoL
between the H&Y stages)—this too caused a significant
increase in the ICER because the utility weights allowed
less differentiation between the health states used in the
model. One further study reported separate utility weights
for each level of ‘OFF’ time [61]; applying these utilities in
the model also led to a higher ICER.
Varying the per-cycle drug cost in the DBS arm caused
variation in the ICER, since this cost was applied in every
model cycle. When the cost was set equal to the equivalent
cost in the BMT arm, the ICER increased to around
£33,079 per QALY gained. Similarly, the cost of the DBS
implantation procedure represented a significant compo-
nent of the overall cost in the DBS arm; thus, variability in
this input altered the ICER. However, the procedure cost
would need to be doubled in order for the ICER to go
above £30,000 per QALY. The proportion of infections
which require a full DBS system explantation and the cost
of fall-related hospitalisations also had an impact upon the
ICER, but to a lesser extent.
Discussion
Based on this cost-effectiveness analysis, using a Markov
model and patient-level data from a randomised controlled
trial, DBS in combination with BMT offers value for
money to UK payers for the treatment of PD, with an ICER
of £20,678 per QALY gained compared to BMT alone over
a 5-year period. This ICER is below the NICE cost-effec-
tiveness threshold and compares favourably with existing
interventions funded on the NHS [62, 63]. The model
improves upon previous economic evaluations by capturing
changes in both H&Y stage and level of ‘OFF’ time for
each intervention, and used a 5-year horizon to ensure that
the costs of DBS battery replacements were accounted for.
The high up-front device and surgery costs were out-
weighed by gains in QoL and reduced drug use. Although
the model predicted minimal survival gain, the benefit of
DBS was gained through improvements in H&Y stage and
‘OFF’ time, which led to gains in quality of life and thus
quality-adjusted survival. The key aspect of the model was
the initial benefit of DBS, and the sensitivity analyses have
demonstrated that the results are sensitive to changes in the
QoL inputs and the costs of on-going drug therapy. Since
many parameters in the model were common to both arms,
the impact of changing these parameters was minimal.
There are currently few economic evaluations of DBS
against which to compare the results of this study. One
study reported an ICER of €34,389 per QALY gained for
DBS versus BMT using a 1-year time horizon, based on a
longitudinal study of patients with advanced PD [39], a
result which was largely driven by significant QoL gains
for patients on DBS; the short time horizon used may
explain the higher ICER derived from the analysis than in
Fig. 4 * Schrag et al. [60] reported utilities by H&Y class: 0.96
(H&Y 1); 0.65 (H&Y 2); 0.26 (H&Y 3); 0.19 (H&Y 4); -0.21 (H&Y
5). There is a greater discrepancy between the H&Y stages in this
study than in the base-case analysis. ** Shimbo et al. [59] utilities:
0.708 (H&Y 1); 0.678 (H&Y 2); 0.622 (H&Y 3); 0.547 (H&Y 4);
0.451 (H&Y 5). There is less discrepancy between the H&Y stages in
this study than in the base-case analysis. In both of these scenarios,
the H&Y utilities were applied across all levels of ‘OFF’ time. The
most influential parameters are shown at the top of the chart
112 J Neurol (2014) 261:106–116
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the results presented here. A second cost-effectiveness
analysis comparing DBS and BMT reported an ICER of
$49,194 per QALY gained over a lifetime horizon, though
this study used Markov states based around nursing home
residency rather than the underlying disease, and many of
the input parameters were not evidence-based [40]. The
ICER from our analysis is consistent with that reported by
NICE (£19,500 per QALY gained) in the clinical guide-
lines for PD [38]; this study also used a 5-year horizon but
did not formally model a disease process, instead calcu-
lating QALYs based on percentage changes in UPDRS
scores. Our study is also consistent with the 5-year cost-
utility (ICER €27,958 per QALY) resulting from a recent
German Markov model analysis [42]. Our model used a
5-year horizon to capture longer-term costs and outcomes
and, by modelling progression in terms of H&Y stage and
level of ‘OFF’ time using patient-level data, offers a real-
istic representation of the course of the disease.
To validate the prediction of long-term outcomes for
patients in the model, we compared the predicted H&Y
mix for DBS patients against 2-year data reported in a
previous study [32, 64]. Our model predicted a mean H&Y
stage of 2.91 amongst surviving DBS patients at 2 years
(from a baseline of 3.62), compared with 3.0 from the
2-year study (from a baseline value of 3.4) (Additional
follow-up data from the PD SURG study will be important
in further validation of our model. A comparison of the
mortality rates predicted by our model against existing
literature on survival for patients with PD suggests that our
model may over-estimate survival times. Several clinical
studies have shown significantly higher mortality rates than
those predicted by the model, with 8–10-year mortality
ranging from 38 to 92 % [65, 66]. Much of this difference
can be accounted for by comparing the age profile of
patients in these studies (mean age at baseline 70–75 years)
with the baseline age of patients in our model (60.5 years,
based on the key clinical study [31]). By modifying the
baseline age of patients in the model to 75 years, the pre-
dicted mortality estimates correlated more closely with the
clinical evidence.
A number of aspects of the analysis warrant further
discussion with respect to uncertainty in long-term out-
comes, transferability of data and disease status indicators.
The key limitation of the study is that the clinical benefit
projected for patients on DBS is based largely around
short-term evidence, extrapolated to a 5-year horizon using
alternative data sources. The model would benefit from
trial data with a longer follow-up period, which would
allow the persistence of the treatment effect to be more
robustly represented. The model was not sensitive to
changes in the long-term disease progression inputs, since
they were applied to both arms of the model—treatment-
specific long-term data would enable this to be explored in
more detail. The PD SURG study should help to address
this data gap [33].
Secondly, the QoL data used in the model do not come
from a study of DBS, and therefore the transferability of
this data is uncertain. The model assumed that QoL is
related to H&Y stage and level of ‘OFF’ time, which
allowed differentiation between the treatment arms in the
calculation of QALYs; however, treatment-specific utility
data would address this aspect of the model more appro-
priately. The current evidence based contains a wide range
of utility weights for patients with PD, and we have eval-
uated the impact of these within the sensitivity analysis.
Related to this, a recent review of economic modelling
studies in interventions for PD noted that, of the 18 model-
based evaluations assessed, none addressed the issue of
non-motor symptoms (e.g., dementia, depression, sleep
disorders), instead focusing entirely on motor-related out-
comes [67]. Studies have shown that non-motor symptoms
can have a significant impact upon patients’ QoL [11, 68,
69], and further data on the impact of treatment upon such
symptoms and the associated effect upon QoL would help
to fully capture this aspect of the disease. Our model has
addressed this by assigning utility weights according to
both H&Y stage and ‘OFF’ time, thus capturing a broader
range of the disease aspects which influence QoL.
Thirdly, the model predicted that DBS provides a small
survival benefit over BMT. Although evidence does exist
to suggest a survival benefit for DBS patients [70], this was
a single-centre study and further evidence is required to
support this outcome. The sensitivity analysis undertaken,
however, suggests that when the mortality risk is set to be
equal across all health states, there is minimal impact on
the cost-effectiveness results, so this appears to be more an
issue of face validity.
Still, despite these limitations, the model captures the
most important aspects of costs and effects of the addition
of DBS to BMT and how they compare with those of
standard BMT in the longer-term, thus providing important
information on the value for money of the therapy for
evidence-based decision-making. This analysis was
undertaken from the UK perspective; adaptations to other
countries will complement the cost-effectiveness evidence
on DBS. Future analyses also need to assess the cost-
effectiveness of DBS in patients with early stage disease,
who have also recently shown to benefit from DBS on a
range of outcomes [71, 72].
Conclusions
This evaluation suggests that DBS may be considered a
cost-effective intervention from a UK payer perspective
when compared with BMT alone (ICER £20,678) in
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patients with advanced PD eligible for surgery, providing
good value for money to payers. Parkinson’s disease is a
complex condition, and this Markov model has captured
the key aspects of the disease in terms of both disease and
economic outcomes. Further evidence on long-term disease
outcomes, including quality of life, plus head-to-head trial
evidence against other comparators in this indication,
would be valuable in facilitating further research on the
economic aspects of these interventions. Unfortunately, the
treatment outcome of pump-administered drug infusion
therapies is much less established according to evidence-
based medicine criteria, and authoritative economic data on
these therapies are rare. Early estimates suggest higher
costs for pump-administered drug infusion therapies, but
future studies are needed for comparisons.
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